News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ALK-Abello A/S Announces Posting Of Briefing Documents For FDA Advisory Committee Meeting On The Ragweed Sublingual Tablet



1/24/2014 9:21:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has posted briefing documents for the Allergenic Products Advisory Committee meeting on 28 January to review Merck’s Biologic License Application (BLA) for the investigational ragweed sublingual allergy immunotherapy tablet.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES